Enlivex Therapeutics (ENLV) News Today → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free ENLV Stock Alerts $1.44 -0.01 (-0.69%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEnlivex Therapeutics (NASDAQ:ENLV) Given "Buy" Rating at HC Wainwrightamericanbankingnews.com - April 24 at 4:42 AMEnlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritisfinance.yahoo.com - April 22 at 8:41 AMYet Another Biotech Stock Has Found Success During Tuesday's Sessionmsn.com - April 18 at 2:11 AMEnlivex Therapeutics (ENLV) Price Target Decreased by 41.67% to 7.14msn.com - April 17 at 10:11 AMEnlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritisfinance.yahoo.com - April 16 at 8:19 AMEnlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritisglobenewswire.com - April 16 at 7:50 AMEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra(TM) In Patients With Sepsisstockhouse.com - April 13 at 2:33 PMEnlivex Therapeutics (NASDAQ:ENLV) Price Target Cut to $7.00 by Analysts at HC Wainwrightmarketbeat.com - April 12 at 8:14 AMEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsisfinance.yahoo.com - April 11 at 7:35 PMEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsisglobenewswire.com - April 11 at 2:58 PMNasdaq Gains Over 50 Points; US Producer Prices Increase In Marchmsn.com - April 11 at 2:35 PMDow Dips 100 Points; CarMax Earnings Miss Viewsmsn.com - April 11 at 2:35 PMEnlivex stock plunges 50% on mixed results from sepsis studymsn.com - April 11 at 2:35 PMEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsisglobenewswire.com - April 11 at 8:05 AMENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023msn.com - April 5 at 11:12 AMEnlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 15.4% in Marchmarketbeat.com - April 2 at 9:24 PMEnlivex Therapeutics (ENLV) Set to Announce Quarterly Earnings on Tuesdaymarketbeat.com - April 1 at 11:36 AMEnlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVfinanznachrichten.de - March 22 at 7:35 PMShort Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Expands By 51.2%marketbeat.com - March 16 at 5:36 PMENLV Apr 2024 7.500 callfinance.yahoo.com - March 16 at 2:24 AMEnlivex Therapeutics Ltd.edition.cnn.com - March 9 at 7:06 PMEnlivex Therapeutics (NASDAQ:ENLV) Trading Up 6.5%marketbeat.com - March 5 at 2:21 AMEnlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritisfinance.yahoo.com - February 26 at 9:29 AMEnlivex Therapeutics Stock (NASDAQ:ENLV), Short Interest Reportbenzinga.com - February 22 at 1:01 PMENLV May 2024 5.000 putfinance.yahoo.com - February 22 at 8:00 AMEnlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Methodfinance.yahoo.com - February 7 at 10:08 AMEnlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritisfinance.yahoo.com - January 17 at 8:49 AMEnlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsisfinance.yahoo.com - December 20 at 8:34 AMEnlivex Therapeutics Ltd ENLVmorningstar.com - December 16 at 6:19 PMIs Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - December 12 at 8:46 AMMediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officerfinance.yahoo.com - November 21 at 7:37 AMEnlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Resultsfinance.yahoo.com - September 11 at 8:49 AMEnlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 7 at 6:56 PMEnlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19finance.yahoo.com - August 2 at 6:54 PMEnlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsisfinance.yahoo.com - July 31 at 9:30 AMEnlivex Announces First Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - June 26 at 9:25 AMThis Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To Cancerbenzinga.com - June 16 at 2:03 PMEnlivex to Present at the 2023 Jefferies Healthcare Conferencefinance.yahoo.com - June 6 at 9:44 AMEnlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapyfinance.yahoo.com - May 31 at 10:09 AMEnlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapyfinance.yahoo.com - May 8 at 8:21 AMEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra(TM) in Patients Receiving CAR T-Cell Therapymarketwatch.com - April 20 at 8:32 AMEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapyfinance.yahoo.com - April 19 at 10:19 AMEnlivex Appoints Andrew Singer to its Board of Directorsfinance.yahoo.com - April 17 at 12:55 PMAnalysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trialsfinance.yahoo.com - April 14 at 1:18 PMEnlivex Therapeutics Ltd.: Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumorsfinanznachrichten.de - April 12 at 3:23 PMEnlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumorsbenzinga.com - April 11 at 12:49 PMHC Wainwright & Co. Reiterates Enlivex Therapeutics (ENLV) Buy Recommendationmsn.com - April 5 at 7:25 PMH.C. Wainwright Sticks to Their Buy Rating for Enlivex (ENLV)markets.businessinsider.com - April 5 at 9:23 AMEnlivex Therapeutics Ltd: Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updatesfinanznachrichten.de - April 4 at 9:33 AMEnlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updatesfinance.yahoo.com - April 4 at 9:33 AM Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. ENLV Media Mentions By Week ENLV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENLV News Sentiment▼-0.200.32▲Average Medical News Sentiment ENLV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENLV Articles This Week▼40▲ENLV Articles Average Week Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: APM News Today FBRX News Today SLGL News Today EYEN News Today ACXP News Today ALRN News Today VIRX News Today UBX News Today SPRB News Today SNSE News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENLV) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
